Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Theravance Biopharma (TBPH) Cost of Revenue: 2014-2018

Historic Cost of Revenue for Theravance Biopharma (TBPH) over the last 4 years, with Mar 2018 value amounting to $826,000.

  • Theravance Biopharma's Cost of Revenue rose 46.19% to $826,000 in Q1 2018 from the same period last year, while for Mar 2018 it was $6.3 million, marking a year-over-year increase of 134.65%. This contributed to the annual value of $6.0 million for FY2017, which is 108.36% up from last year.
  • Theravance Biopharma's Cost of Revenue amounted to $826,000 in Q1 2018, which was down 73.49% from $3.1 million recorded in Q4 2017.
  • Theravance Biopharma's Cost of Revenue's 5-year high stood at $3.2 million during Q4 2014, with a 5-year trough of $188,000 in Q1 2014.
  • For the 3-year period, Theravance Biopharma's Cost of Revenue averaged around $1.1 million, with its median value being $826,000 (2018).
  • In the last 5 years, Theravance Biopharma's Cost of Revenue crashed by 64.20% in 2016 and then skyrocketed by 196.69% in 2017.
  • Over the past 5 years, Theravance Biopharma's Cost of Revenue (Quarterly) stood at $3.2 million in 2014, then fell by 0.65% to $3.2 million in 2015, then crashed by 64.20% to $1.1 million in 2016, then skyrocketed by 171.90% to $3.1 million in 2017, then surged by 46.19% to $826,000 in 2018.
  • Its last three reported values are $826,000 in Q1 2018, $3.1 million for Q4 2017, and $985,000 during Q3 2017.